Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

ABSTRACT: A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

PROVIDER: PRJNA820009 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18490700_1.fastq.gz	Fastqsanger.gz
	SRR18490700_2.fastq.gz	Fastqsanger.gz
	SRR18490701_1.fastq.gz	Fastqsanger.gz
	SRR18490701_2.fastq.gz	Fastqsanger.gz
	SRR18490702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 372

Similar Datasets

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-05-03 | GSE199336 | GEO

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Project description:A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

| PRJNA1085755 | ENA

RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants

Project description:RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants

| PRJNA574846 | ENA

The cellular hierarchy of acute myeloid leukemia informs personalized treatment

Project description:Acute myeloid leukemia (AML) is characterized by malignant myeloid precursors that span a cellular hierarchy from dedifferentiated leukemic stem cells to mature blasts. While the diagnostic and prognostic importance of AML blast maturation is increasingly recognized, personalized therapies are currently not tailored to a patient’s individual makeup of this cellular hierarchy. In this study, we use multiplexed image-based ex vivo drug screening (pharmacoscopy) to systematically quantify the drug sensitivity across the cellular hierarchy of AML patients. We analyzed 174 prospective and longitudinal patient samples from 44 newly diagnosed AML patients, which indicated that differences in the AML hierarchy significantly identified poor responses to first-line therapy, outperforming European LeukemiaNet (ELN) criteria. Critically, drug response profiling across the AML hierarchy of each patient improved the accuracy of predicting patient response to first-line therapy (AUC 0.91), and revealed alternative individualized treatment options targeting the complete AML hierarchy of non-responding patients. We confirmed these findings in an independent cohort of 26 relapsed/refractory AML patients, for whom pan-hierarchy response profiling improved response predictions post hoc. Overall, our results quantify the clinical importance of therapeutically targeting the complete cellular hierarchy of newly diagnosed AML, and identify multiplexed image-based ex vivo drug screening to enable quantification and targeting of the AML maturation hierarchy for improved personalized treatment.

2024-07-20 | GSE272681 | GEO

social hierarchy

Project description:social hierarchy Raw sequence reads

| PRJNA1108947 | ENA

Comprehensive Study of Nuclear Receptor DNA Binding Provides a Revised Framework for Understanding Receptor Specificity

Project description:Comprehensive Study of Nuclear Receptor DNA Binding Provides a Revised Framework for Understanding Receptor Specificity

| PRJNA514306 | ENA

Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework

Project description:Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework

| PRJNA964441 | ENA

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Project description:Precision medicine's potential to transform complex autoimmune-disease treatment is often challenged by limited data availability and inadequate sample size when compared to the number of molecular features found in high-throughput multi-omics datasets. Addressing this issue, the novel framework PRoBeNet (Predictive Response Biomarkers using Network medicine) was developed. ProBeNet operates under the hypothesis that the therapeutic effect of a drug propagates through a protein–protein interaction network to reverse disease states. ProBeNet prioritizes biomarkers by considering (1) therapy-targeted proteins, (2) disease-specific molecular signatures, and (3) an underlying network of interactions among cellular components (the human interactome). With ProBeNet, biomarkers were discovered predicting patient responses to both an established autoimmune therapy (infliximab) and an investigational compound (a MAPK3/1 inhibitor). Predictive power of ProBeNet biomarkers was validated with retrospective gene-expression data from ulcerative-colitis and rheumatoid-arthritis patients and prospective data from ulcerative-colitis and Crohn’s disease patient-derived tissues. Machine-learning models using ProBeNet biomarkers significantly outperformed models using either all genes or randomly selected genes, especially when data were limited (fewer than 20 samples). These results illustrate the value of ProBeNet for reducing features and for constructing robust machine-learning models when limited data are available. ProBeNet may be used to develop companion and complementary diagnostic assays for complex autoimmune-disease therapies, which may help stratify suitable patient subgroups in clinical trials, approve new drugs, and improve patient outcomes.

2024-03-13 | GSE261205 | GEO

Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework II

Project description:Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework II

| PRJNA964442 | ENA

Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework I

Project description:Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework I

| PRJNA964443 | ENA